---
title: "FDA panel split on risk and benefit of Symplicity Spyral renal denervation system"
date: "2023-08-24T15:01:19.000Z"
publishedDate: "24 août 2023"
summary: "The US Food and Drug Administration (FDA) Circulatory Systems Devices Panel met yesterday (23 August) to review evidence of the safety and efficacy of Medtronic’s Symplicity Spyral renal denervation system, with committee members split on the motion that the benefits of the device outweigh the risks for use in patients with hypertension. The Circulatory Systems [&#8230;] The post FDA panel split on risk and benefit of Symplicity Spyral renal denervation system appeared first on Vascular News ."
importance: ""
sourceUrl: "https://vascularnews.com/fda-panel-symplicity-spyral-renal-denervation/"
tags: ["France", "Actualité", "Vascular News — Latest"]
permalink: "/papers/2023-08-24-fda-panel-split-on-risk-and-benefit-of-symplicity-spyral-renal-denervation-system"
imageUrl: "https://vascularnews.com/wp-content/uploads/sites/7/2023/08/Medtronic-Symplicity-1.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://vascularnews.com/fda-panel-symplicity-spyral-renal-denervation/"
---

![FDA panel split on risk and benefit of Symplicity Spyral renal denervation system](https://vascularnews.com/wp-content/uploads/sites/7/2023/08/Medtronic-Symplicity-1.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://vascularnews.com/fda-panel-symplicity-spyral-renal-denervation/*

## L’essentiel

The US Food and Drug Administration (FDA) Circulatory Systems Devices Panel met yesterday (23 August) to review evidence of the safety and efficacy of Medtronic’s Symplicity Spyral renal denervation system, with committee members split on the motion that the benefits of the device outweigh the risks for use in patients with hypertension. The Circulatory Systems [&#8230;] The post FDA panel split on risk and benefit of Symplicity Spyral renal denervation system appeared first on Vascular News .

## Lien source

https://vascularnews.com/fda-panel-symplicity-spyral-renal-denervation/
